403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Integral Biosystems To Present On The Nanom-Wafer Technology At ARVO 2026
(MENAFN- EIN Presswire) EINPresswire/ -- Bedford, MA-based Integral BioSystems will present at the Annual ARVO Convention to be held May 3-May 7, 2026 at Denver, Colorado.
The OcuHeal-UV400+ product is one in the pipeline of products-in-development, based on a lipid nanoparticle (LNP) platform technology developed by Integral BioSystems. OcuHeal-UV400+ product incorporates a GRAS (generally regarded as safe), plant-based compound into nanostructured, liquid-crystalline lipid nanoparticles. The compound has a high molar extinction coefficient and blocks both UV-A and UV-B, with further blocking of blue light generated by the encapsulated LNP. The encapsulated compound is biocompatible with, and protective of corneal epithelial cells, quenches reactive free radicals generated by various stressors (like particulate pollution) and elicits anti-fibrotic healing in injured corneal tissues. With worldwide reports of ocular tissue disorders caused by UV radiation (both UVA and UVB), this product promises to be transformational. Furthermore, this product, when commercialized, will have clinical utility to persons suffering from digital strain from prolonged computer use.
Presentation Number - Posterboard Number: 2968 - 0144
Abstract/Presentation Title: Once-Weekly Administration of Medications via NanoM-WaferTM Platform for Treatment of Corneal Surface Disorders
Presentation Type: Poster Session
Session Number: 341
Session Title: Corneal disease and drug delivery
Session Date/Times: May 5, 2026 from 1:15 PM to 3:00 PM
Authors are Kevin Ward, Akshita Bhardwaj, Sagan Stanczak, Ivan Guerrero, Shikha Barman
Integral BioSystems is a specialty drug delivery contract research firm focused on formulation and analytical development of both small molecule and biologics. Integral's hybrid business model has enabled the development of its own proprietary innovations. In particular, scientific experts at Integral have conceptualized and designed both the OcuHealTM and NanoM-WaferTM technologies. Both technologies have been fully patented in 14 global jurisdictions, including Europe, US, Canada, India, China and Japan. Additionally, the evolving nature of the technologies have resulted in additional PCT applications.
If interested in partnering with Integral BioSystems, please reach out to the business development team at....
The OcuHeal-UV400+ product is one in the pipeline of products-in-development, based on a lipid nanoparticle (LNP) platform technology developed by Integral BioSystems. OcuHeal-UV400+ product incorporates a GRAS (generally regarded as safe), plant-based compound into nanostructured, liquid-crystalline lipid nanoparticles. The compound has a high molar extinction coefficient and blocks both UV-A and UV-B, with further blocking of blue light generated by the encapsulated LNP. The encapsulated compound is biocompatible with, and protective of corneal epithelial cells, quenches reactive free radicals generated by various stressors (like particulate pollution) and elicits anti-fibrotic healing in injured corneal tissues. With worldwide reports of ocular tissue disorders caused by UV radiation (both UVA and UVB), this product promises to be transformational. Furthermore, this product, when commercialized, will have clinical utility to persons suffering from digital strain from prolonged computer use.
Presentation Number - Posterboard Number: 2968 - 0144
Abstract/Presentation Title: Once-Weekly Administration of Medications via NanoM-WaferTM Platform for Treatment of Corneal Surface Disorders
Presentation Type: Poster Session
Session Number: 341
Session Title: Corneal disease and drug delivery
Session Date/Times: May 5, 2026 from 1:15 PM to 3:00 PM
Authors are Kevin Ward, Akshita Bhardwaj, Sagan Stanczak, Ivan Guerrero, Shikha Barman
Integral BioSystems is a specialty drug delivery contract research firm focused on formulation and analytical development of both small molecule and biologics. Integral's hybrid business model has enabled the development of its own proprietary innovations. In particular, scientific experts at Integral have conceptualized and designed both the OcuHealTM and NanoM-WaferTM technologies. Both technologies have been fully patented in 14 global jurisdictions, including Europe, US, Canada, India, China and Japan. Additionally, the evolving nature of the technologies have resulted in additional PCT applications.
If interested in partnering with Integral BioSystems, please reach out to the business development team at....
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment